Literature DB >> 8842845

Prevention of variceal rebleeding and treatment of liver carcinoma by consecutive transjugular intrahepatic portosystemic shunt and hepatic artery chemoembolization.

A Nicolini1, S Saccheri, A Lovaria, A Maggi, M Cazzaniga, A Panzeri, F Salerno.   

Abstract

Variceal bleeding and hepatocellular carcinoma are two severe complications of cirrhosis. One of our patients who bled from oesophageal varices was found to have a malignant hepatic nodule. As the patient refused liver transplantation, a transjugular intrahepatic portosystemic stent was carried out for portal hypertension, and transcatheter arterial chemoembolization for cancer. Both procedures were successful and one year later liver function has not deteriorated. This case shows that intrahepatic stent placement and selective arterial chemoembolization can be safely performed in cirrhotic patients with a solitary hepatocarcinoma nodule and a good liver function reserve.

Entities:  

Mesh:

Year:  1996        PMID: 8842845

Source DB:  PubMed          Journal:  Ital J Gastroenterol        ISSN: 0392-0623


  3 in total

1.  Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt.

Authors:  Zhu Wang; Hailong Zhang; He Zhao; Xiaoze Wang; Jiaywei Tsauo; Xuefeng Luo; Xiao Li
Journal:  Diagn Interv Radiol       Date:  2014-11       Impact factor: 2.630

Review 2.  Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law.

Authors:  Gerond Lake-Bakaar; Muneeb Ahmed; Amy Evenson; Alan Bonder; Salomao Faintuch; Vinay Sundaram
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

3.  Transjugular intrahepatic portosystemic shunt for palliative treatment of portal hypertension secondary to portal vein tumor thrombosis.

Authors:  Zai-Bo Jiang; Hong Shan; Xin-Ying Shen; Ming-Sheng Huang; Zheng-Ran Li; Kang-Shun Zhu; Shou-Hai Guan
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.